A comparative study of metformin and nicotinamide riboside in alleviating tissue aging in rats.

Life medicine Pub Date : 2022-10-26 eCollection Date: 2023-02-01 DOI:10.1093/lifemedi/lnac045

Lingling Geng, Bin Zhang, Haisong Liu, Si Wang, Yusheng Cai, Kuan Yang, Zhiran Zou, Xiaoyu Jiang, Zunpeng Liu, Wei Li, Zeming Wu, Xiaoqian Liu, Qun Chu, Guang-Hui Liu, Jing Qu, Weiqi Zhang

{"title":"A comparative study of metformin and nicotinamide riboside in alleviating tissue aging in rats.","authors":"Lingling Geng, Bin Zhang, Haisong Liu, Si Wang, Yusheng Cai, Kuan Yang, Zhiran Zou, Xiaoyu Jiang, Zunpeng Liu, Wei Li, Zeming Wu, Xiaoqian Liu, Qun Chu, Guang-Hui Liu, Jing Qu, Weiqi Zhang","doi":"10.1093/lifemedi/lnac045","DOIUrl":null,"url":null,"abstract":"Metformin (MET) and nicotinamide riboside (NR) have both been reported to exert geroprotective effects in multiple species. However, the mechanism by which MET and NR regulate the aging program and delay aging in multiple tissues remains unclear. Here, we demonstrated that MET and NR attenuate aging features in human mesenchymal stem cells. Moreover, by systematically investigating the pathophysiological changes in different tissues from aged rats after oral administration of MET and NR, we showed that both MET and NR treatment alleviated various aging-related characteristics in multiple tissues, including inflammation, fibrosis, and protein aggregates. Consistently, MET or NR treatment partially rescued aging-related gene expression changes in aged rats. Collectively, we report that both MET and NR attenuate senescence phenotypes in human stem cells in vitro and in a variety of rodent tissues in vivo, thus providing a valuable resource and foundation for further evaluation of these two compounds against aging.","PeriodicalId":74073,"journal":{"name":"Life medicine","volume":" ","pages":"lnac045"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749560/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/lifemedi/lnac045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Metformin (MET) and nicotinamide riboside (NR) have both been reported to exert geroprotective effects in multiple species. However, the mechanism by which MET and NR regulate the aging program and delay aging in multiple tissues remains unclear. Here, we demonstrated that MET and NR attenuate aging features in human mesenchymal stem cells. Moreover, by systematically investigating the pathophysiological changes in different tissues from aged rats after oral administration of MET and NR, we showed that both MET and NR treatment alleviated various aging-related characteristics in multiple tissues, including inflammation, fibrosis, and protein aggregates. Consistently, MET or NR treatment partially rescued aging-related gene expression changes in aged rats. Collectively, we report that both MET and NR attenuate senescence phenotypes in human stem cells in vitro and in a variety of rodent tissues in vivo, thus providing a valuable resource and foundation for further evaluation of these two compounds against aging.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

二甲双胍与烟酰胺核苷缓解大鼠组织衰老的比较研究

二甲双胍(Metformin, MET)和烟酰胺核苷(nictinamide riboside, NR)均被报道在多个物种中发挥老年保护作用。然而，MET和NR在多个组织中重新连接衰老程序并延缓衰老的机制尚不清楚。在这里，我们证明MET和NR可以减缓人间充质干细胞的衰老特征。此外，通过系统研究老年大鼠口服MET和NR后不同组织的病理生理变化，我们发现MET和NR治疗均可缓解多种组织中与衰老相关的特征，包括炎症、纤维化和蛋白质聚集。一致地，MET或NR治疗部分地挽救了衰老大鼠的衰老相关基因表达变化。总之，我们报告了MET和NR在体外和体内多种啮齿动物组织中减轻人类干细胞的衰老表型，从而为进一步评估这两种化合物的抗衰老能力提供了宝贵的资源和基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Life medicine

自引率

0.00%

发文量